AFT Pharmaceuticals has announced it has submitted to the US Food and Drug Administration data the regulator requested as it considers registration of the company's patented intravenous pain relief medicine Maxigesic IV.
In a delay to the registration of the medicine in the US, the FDA requested in Jul 2022 additional data on the performance of Maxigesic IV's primary packaging (the glass vial in which the medicine is stored and the vial's stopper).
AFT along with its commercialisation partner Belgium's Hyloris Pharmaceuticals has over the last year collated the data and submitted today.
AFT Managing Director Dr Hartley Atkinson said, "we believe the data we have submitted will satisfy the FDA's requirements and remove the outstanding hurdle to registration.
"All going well we anticipate registration of the medicine this year and sales to follow shortly after."
Maxigesic IV is a combination of 1,000mg paracetamol and 300mg ibuprofen solution for infusion, for the treatment of post-operative pain, and is currently licensed in more than 100 countries across the globe.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Apr 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Apr 23
Warning: Undefined variable $o_shortcode_atts in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1263
Warning: Undefined variable $output in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1266
